The FDA’s Pharmacy Compounding Advisory Committee closed its two-day meeting on July 24 having recommended six of the seven peptides under review for the Section 503A Bulk Drug Substances List. Only emideltide, also known as DSIP, failed to pass, falling 6 to 7 with one abstention. On July 23, the committee voted 8 to 6, …
More
FDA Panel Recommends Six of Seven Peptides for Compounding, Rejects Emideltide
FDA Warns San Diego Pharmacist Over Unapproved Retatrutide and Tirzepatide Sales
Bernard Gramlich, founder of GRAM peptides and a former Rancho Santa Fe pharmacist, has agreed to stop selling retatrutide and tirzepatide injections online after receiving a formal warning letter from the FDA in March, according to reporting from 10News San Diego. The products were sold alongside bacteriostatic water for injection, despite the site’s stated research …
More
RFK, the FDA, and Seven Peptides: What to Expect from the July 2026 PCAC Review
Industry Pulse › RFK and the FDA July 2026 Peptide Decision May 24, 2026 · Regulatory Research Use Only. This article analyzes upcoming FDA regulatory activity in the context of research peptide supply chains. Genevium peptides are intended strictly for laboratory research purposes. Not approved for human consumption, clinical, therapeutic, veterinary, or diagnostic use. For …
More
What the Peptide Sciences Shutdown Revealed: A Supplier-Side Analysis of Research Peptide Operations in 2026
Industry Pulse › What the Peptide Sciences Shutdown Revealed May 23, 2026 · Research In March 2026, Peptide Sciences voluntarily ceased operations. The company had been one of the largest U.S. research peptide suppliers for more than a decade, with an estimated $7.4 million in monthly revenue and a customer base spanning academic laboratories, independent …
More
The FDA Peptide Reclassification of 2026: What Actually Changed, What’s Pending, and What It Means for Research Suppliers
Industry Pulse › The FDA Peptide Reclassification of 2026 May 23, 2026 · Regulatory In the first half of 2026, the FDA built and deployed a framework. The framework is clinical need, and it is now the lens through which every peptide compounding question will be evaluated going forward. Three regulatory actions between February and …
More
FDA Reverses Course on Seven Peptides: PCAC Reviews BPC-157, TB-500, KPV in July
The FDA Pharmacy Compounding Advisory Committee will convene July 23-24, 2026 to consider adding BPC-157, TB-500, KPV, Semax, Epitalon and others to the 503A bulks list. If recommended, compounding pharmacies could legally prepare these compounds for the first time.
More
What “Research Use Only” Actually Means: The Legal Distinction Researchers and Buyers Keep Conflating
Research use only peptides occupy a narrow legal category that buyers and sellers increasingly treat as a generic disclaimer. As FDA enforcement intensifies in 2026, the RUO line is becoming the dividing line between legitimate laboratory commerce and federal regulatory exposure.
MoreGlow Peptide Research: BPC-157, TB-500, GHK-Cu
Research Hub › Skin & Cosmetic › Glow Peptide Research Research Use Only. The information on this page summarizes published peptide research for laboratory and educational reference. The compounds discussed are intended exclusively for in vitro and non-clinical research. Nothing on this page constitutes medical advice or describes human use, diagnosis, treatment, or therapeutic application. …
More-
The Peptide Wild West Hits Mainstream Media: What the Coverage Misses About Research Suppliers
Industry Pulse › The Peptide Wild West Hits Mainstream Media May 3, 2026 · Trends In the last seven days, at least eight major outlets including Fox News, CBS News, The Hill, Medscape, and MDLinx have published variations of the same story: the peptide market is a “Wild West” where unregulated injectables, social-media hype, and …
More